2024 marked a transformative year for Switzerland’s regulatory authority, Swissmedic. As part of its ambitious 2023–2026 strategy, the agency made significant strides towards digital transformation and improving access to innovative medicines while delivering a notable 12 percent increase in new drug approvals with 46 new active substances.
Drive for Digital Transformation and Innovation
2024 was a busy year for the Swiss agency. Building on its multi-year strategy, the regulator accelerated its modernisation efforts by rolling out three new digital platforms designed to streamline processes and enhance regulatory efficiency. The launch of pilot programmes like the Swissmedic Innovation Office also underscored the agency's commitment to speeding up access to innovation.Focus Areas: Oncology Leads the Way
Among the 46 substances approved in 2024, oncology and haematology treatments dominated, accounting for 30 percent of all approvals, followed by infectiology and vaccines, as well as neurology and psychiatry, each comprising 13 percent of the total.
Despite the uptick in approvals, Swissmedic maintained stable turnaround times, signaling that increased volume did not come at the expense of review efficiency.
Hecho con Visme Infographic Maker
